Specifically, in COVID-19 patients, SARS-CoV-2 may trigger development of DM due to direct pancreatic β-cell injury of SARS-CoV-2 due to a higher expression of ACE2, a receptor for this virus, or indirectly through induction of insulin resistance triggered by SARS-CoV-2-induced oxidative stress (129). This evidence concerns the gene ACE2 and COVID-19.